DUBLIN, Sept. 21,
2023 /PRNewswire/ -- Endo International plc (OTC:
ENDPQ) announced today that data from clinical studies of
collagenase clostridium histolyticum (CCH) in patients with plantar
fibromatosis will be presented during the American Orthopaedic Foot
& Ankle Society's (AOFAS) annual scientific meeting. The
meeting is taking place through September
23 in Louisville,
Kentucky.
Three presentations cover data from the Phase 1 clinical study
of CCH in patients with plantar fibromatosis. Results demonstrated
improvement in nodule hardness and in patient and physician
satisfaction scores. In addition, the CCH safety profile was
consistent with the known CCH safety profile from other clinical
studies and indications. Most adverse events were rated as mild to
moderate, and there were no reported treatment-related serious
adverse events.
A fourth presentation provides real-world treatment patterns
derived from a retrospective observational study that compiles a
large database of newly diagnosed patients with plantar
fibromatosis. These new data address a gap in our knowledge of
plantar fibromatosis treatments.
"We're pleased to share information and facilitate a better
understanding of plantar fibromatosis in an effort to help improve
treatment outcomes," said James P.
Tursi, MD, Executive Vice President, Global Research &
Development at Endo. "We look forward to presenting our clinical
study data as we explore a potential nonsurgical option in patients
with plantar fibromatosis."
CCH is not approved for use in treating patients with plantar
fibromatosis. Endo has completed a Phase 2 study and anticipates
that the pivotal Phase 3 program will begin later this year.
The four presentations are below:
- NEW: Treatment patterns for plantar fibromatosis in
the United States: a retrospective
observational study (e-poster presentation)
- Authors: Jill Davis, MS;
Aimee Near, MPH; David Hurley, MD; Laurence Djatche, PharmD, MS;
Jenny Tse, MS; Riddhi P. Doshi, PhD, MBBS, MPH; Elizabeth J. Wang, MS; Luis A. Ortega, MD; David G. Armstrong, MD, PhD, MS
- Participant Satisfaction and Investigator Assessment of
Collagenase Clostridium Histolyticum Injection as a Nonsurgical
Intralesional Treatment Option for Plantar Fibromatosis (podium
presentation)
- Authors: Christopher J.
Anderson, DPM; Richard A.
Pollak, DPM; David Hernandez,
MD; Shannon R. Dalton, PhD;
Qinfang Xiang, PhD; Saji Vijayan, MBBS; Luis
Ortega, MD; Joseph M.
Caporusso, DPM
- Safety Data from a Study of Collagenase Clostridium
Histolyticum Injection in Participants With Plantar Fibromatosis
(poster presentation)
- Authors: Richard A. Pollak, DPM;
David Hernandez, MD; Christopher J. Anderson, DPM; Shannon R. Dalton, PhD; Qinfang Xiang, PhD; Saji
Vijayan, MBBS; Luis Ortega,
MD; Joseph M. Caporusso, DPM
- Collagenase Clostridium Histolyticum Injection in Patients With
Plantar Fibromatosis: A Randomized, Open-Label, Dose-Ranging Study
(e-podium presentation)
- Authors: Christopher J.
Anderson, DPM; Luis Ortega,
MD; Joseph M. Caporusso, DPM;
Richard A. Pollak, DPM; David Hernandez, MD; Shannon R. Dalton, PhD; Qinfang Xiang, PhD; Saji
Vijayan, MBBS
About Plantar Fibromatosis
Plantar fibromatosis (PFI)
or Ledderhose disease, sometimes termed "Dupuytren's disease of the
foot," is a hyperproliferative fibrous tissue disorder resulting in
the formation of nodules along the plantar fascia, the thick
connective tissue that supports the arch of the foot, which is
often painful. There is no cure for PFI. Symptom management options
include custom insoles, topical treatments, over-the-counter pain
and anti-inflammatory medications, radiation therapy and steroid
injections, and ultimately, surgery may be required to remove the
nodules.
About Endo
Endo (OTC: ENDPQ) is a specialty
pharmaceutical company committed to helping everyone we serve live
their best life through the delivery of quality, life-enhancing
therapies. Our decades of proven success come from passionate team
members around the globe collaborating to bring treatments forward.
Together, we boldly transform insights into treatments benefiting
those who need them, when they need them. Learn more at
www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
Certain information in this press release may be
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and any applicable
Canadian securities legislation including, but not limited to, the
statements by Dr. Tursi, any statements relating to product
efficacy, clinical trials or studies, potential treatments or
indications, therapeutic outcomes or treatment
responses, safety or adverse events, and any statements that
refer to expected, estimated or anticipated future results or that
do not relate solely to historical facts. Statements including
words or phrases such as "believe," "expect," "anticipate,"
"intend," "estimate," "plan," "will," "may," "look forward,"
"intend," "guidance," "future," "potential" or similar expressions
are forward-looking statements. All forward-looking statements in
this communication reflect the Company's current views as of the
date of this communication about its plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to it and on assumptions it has
made. Actual results may differ materially and adversely from
current expectations based on a number of factors, including, among
other things, the outcome of the Company's contingency planning and
restructuring activities; the timing, impact or results of any
pending or future litigation, investigations, proceedings or
claims, including opioid, tax and antitrust related matters; any
actual or contingent liabilities; settlement discussions or
negotiations; the Company's liquidity, financial performance, cash
position and operations; the risks and uncertainties associated
with chapter 11 proceedings; the time, terms and ability to confirm
a sale of the Company's businesses under Section 363 of the U.S.
Bankruptcy Code; the risk that the Company's chapter 11 cases may
be converted to cases under chapter 7 of the Bankruptcy Code; the
adequacy of the capital resources of the Company's businesses and
the difficulty in forecasting the liquidity requirements of the
operations of the Company's businesses; the unpredictability of the
Company's financial results; the Company's ability to discharge
claims in chapter 11 proceedings; negotiations with the holders of
the Company's indebtedness and its trade creditors and other
significant creditors; the risks and uncertainties with performing
under the terms of the restructuring support agreement and any
other arrangement with lenders or creditors while in chapter 11
proceedings; the performance, including the approval, introduction,
and consumer and physician acceptance of new products and the
continuing acceptance of currently marketed products; and the
Company's ability to obtain and successfully manufacture, maintain
and distribute a sufficient supply of products to meet market
demand in a timely manner. The Company expressly disclaims any
intent or obligation to update these forward-looking statements,
except as required to do so by law.
Additional information concerning risk factors, including those
referenced above, can be found in press releases issued by the
Company, as well as the Company's public periodic filings with the
U.S. Securities and Exchange Commission and with securities
regulators in Canada, including
the discussion under the heading "Risk Factors" in the Company's
most recent Annual Report on Form 10-K and any subsequent Quarterly
Reports on Form 10-Q or other filings with the U.S. Securities and
Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/endo-presents-new-data-at-the-american-orthopaedic-foot--ankle-society-annual-meeting-301934275.html
SOURCE Endo International plc
